Barry M, Flynn D M, Letsky E A, Risdon R A
Br Med J. 1974 Apr 6;2(5909):16-20. doi: 10.1136/bmj.2.5909.16.
A prospective trial of continuous chelation therapy in children with homozygous thalassaemia on a high transfusion regimen was started in April 1966. The effect of treatment on iron concentration in the liver and on hepatic histology was examined in 49 biopsy specimens obtained from nine chelator-treated patients and nine control patients between April 1966 and April 1973.Chelation therapy was associated with a significant reduction in liver iron concentration, and by the end of the trial the values for the two groups showed no overlap. A similar difference was seen in the amount of hepatic fibrosis, which showed little or no change in the chelator-treated patients but was progressive in the controls.No major clinical differences were seen, probably because both groups included several older children who were heavily loaded with iron at the start of the trial. Among the younger patients, however, puberty was delayed in four of five controls but in only one of four chelator-treated children. Prepubertal growth rate was significantly greater in the chelator-treated patients than in the controls.
1966年4月,一项针对接受高输血方案的纯合子地中海贫血患儿进行持续螯合疗法的前瞻性试验启动。1966年4月至1973年4月期间,从9名接受螯合剂治疗的患者和9名对照患者身上获取了49份活检标本,研究了治疗对肝脏铁浓度和肝脏组织学的影响。螯合疗法与肝脏铁浓度的显著降低相关,到试验结束时,两组的值没有重叠。肝纤维化程度也有类似差异,接受螯合剂治疗的患者几乎没有变化或没有变化,而对照组则呈进行性发展。未观察到重大临床差异,可能是因为两组都包括几个在试验开始时铁负荷很重的大龄儿童。然而,在较年轻的患者中,5名对照组中有4名青春期延迟,而接受螯合剂治疗的4名儿童中只有1名青春期延迟。接受螯合剂治疗的患者青春期前的生长速度明显高于对照组。